<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758780</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2020-25</org_study_id>
    <nct_id>NCT04758780</nct_id>
  </id_info>
  <brief_title>Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients</brief_title>
  <acronym>OPALESCENCE</acronym>
  <official_title>Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT (Positron Emission Tomography/Computerized Tomography) in Metastatic Triple Negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Telix Pharmaceutical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SIRIC ILIAD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250)&#xD;
      as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic&#xD;
      triple negative breast cancer (TNBC) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250)&#xD;
      as a novel, Carbonic Anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic&#xD;
      triple negative breast cancer (TNBC) patients.&#xD;
&#xD;
      TNBC patients are known to be rapidly progressive and have a poor prognosis. This poor&#xD;
      prognosis is due to the lack of common breast cancer targets in TNBC. As TNBC expresses CAIX,&#xD;
      this stuy will evaluate CAIX targeting by using a radiolabeled monoclonal antibody that&#xD;
      recognizes carbonic anhydrase IX (CAIX) : 89Zr- girentuximab otherwise known as 89Zr-TLX250.&#xD;
      Previous and ongoing studies have demonstrated the potential application of 89Zr-TLX250 as a&#xD;
      new PET/CT imaging tracer for the detection of renal cancer.&#xD;
&#xD;
      After establishing the TNBC targeting properties of the 89Zr-TLX250 PET/CT imaging tracer, it&#xD;
      should be interesting to develop a new targeted therapy using TLX250- radiolabeled with a&#xD;
      therapeutic radionuclide such as 177Lutétium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Monocentric, open prospective study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the concordance for tumor lesion detection using 89Zr-TLX250 PET/CT versus a conventional 18FDG PET/CT scan</measure>
    <time_frame>35 days</time_frame>
    <description>Assess the concordance for tumor lesion detection using 89Zr-TLX250 PET/CT scan : Positron Emission Tomography/Computerized Tomography scan versus a conventional 18 Fluorodésoxyglucose (18FDG) PET/CT scan where comparison will be made on a per lesion analysis basis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine the percent of total tumor burden (whole body) detected on 89Zr-TLX250 PET/CT scan compared to that defined on 18FDG PET/CT used as the reference</measure>
    <time_frame>35 days</time_frame>
    <description>Percent of positive CA IX metastatic tumor burden compared to total metastatic tumor burden by 18FDG (ratio &quot;Number of positive 89Zr-TLX250 lesions / Number of positive FDG lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the correlation between the Standardized Uptake Values (SUV) of 89Zr-TLX250 and CAIX histological expression if a biopsy is done</measure>
    <time_frame>35 days</time_frame>
    <description>If a metastasis biopsy is conducted, assessment of the correlation between the normalized uptake values (SUV) of 89Zr-TLX250 positive lesions and CAIX histological expression will be done by comparing the 89Zr-TLX250 semi-quantitative data with the immunohistochemical results (IHC) of biopsied metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs measurment after 89Zr-TLX250 injection</measure>
    <time_frame>2 Hours</time_frame>
    <description>Vital signs will be measured within 2 hours after 89Zr-TLX250 injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the generation of Human Anti-Chimeric Antibodies (HACA) in response to the girentuximab</measure>
    <time_frame>3 months</time_frame>
    <description>A blood sample will be drawn before 89Zr-TLX250 injection and 3 months after in order to evaluate the presence of Human anti-chimeric antibody (HACA) in sera of patients. This will be tested quantitatively and qualitatively using validated ELISAs HACA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and Serious Adverse Events related to 89Zr-TLX250 as assessed by CTCAE v5.0</measure>
    <time_frame>30 days</time_frame>
    <description>All Adverse Events and Serious Adverse Events due to 89Zr-TLX250 will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Serious Adverse Events related to 89Zr-TLX250 as assessed by CTCAE v5.0</measure>
    <time_frame>30 days</time_frame>
    <description>All Serious Adverse Events due to 89Zr-TLX250 will be reported</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>89Zr-TLX250 PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pretherapeutic 89Zr-TLX250 PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>89Zr-TLX250 PET/CT</intervention_name>
    <description>Pretherapeutic 89Zr-TLX250 PET/CT</description>
    <arm_group_label>89Zr-TLX250 PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained from the patient prior to performing any&#xD;
             protocol-related procedures, including screening evaluations.&#xD;
&#xD;
          -  Female or male, Age ≥ 18 years at time of study entry.&#xD;
&#xD;
          -  Primitive triple negative breast cancer proven histologically, defined according to&#xD;
             the following criteria:&#xD;
&#xD;
               -  Estrogen receptors &lt;10%.&#xD;
&#xD;
               -  And progesterone receptors &lt;10%.&#xD;
&#xD;
               -  And Human Epidermal Growth factor Receptor 2 (HER2) not amplified or not&#xD;
                  overexpressed.&#xD;
&#xD;
          -  Breast Cancer (BC) recurrence documented by conventional imaging and/or FDG PET/CT&#xD;
             with at least one measurable metastatic lesion according to Response Evaluation&#xD;
             Criteria In Solid Tumors (RECIST) and/or PET Response Criteria In Solid Tumors&#xD;
             (PERCIST).&#xD;
&#xD;
          -  Consent to use a contraception method for at least 30 days after administration of&#xD;
             89Zr-TLX250.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.&#xD;
&#xD;
          -  Life expectancy at least 6 months.&#xD;
&#xD;
          -  Patient has valid health insurance.&#xD;
&#xD;
          -  Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of another primary malignancy except for basal cell carcinoma within the last&#xD;
             5 years.&#xD;
&#xD;
          -  Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the planned&#xD;
             administration of 89Zr-TLX250 or continuing adverse effects (&gt; grade 1) from such&#xD;
             therapy (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0).&#xD;
&#xD;
          -  Planned antineoplastic therapies (for the period between IV administration of&#xD;
             89Zr-TLX250 and imaging).&#xD;
&#xD;
          -  Exposure to murine or chimeric antibodies within the last 5 years.&#xD;
&#xD;
          -  Previous administration of any radionuclide within 10 half-lives of the same.&#xD;
&#xD;
          -  Impossibility to hold lying motionless at least 1 hour, or known claustrophobia.&#xD;
&#xD;
          -  Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic),&#xD;
             that may interfere with the objectives of the study or with the safety or compliance&#xD;
             of the subject, as judged by the investigator.&#xD;
&#xD;
          -  Mental impairment that may compromise the ability to give informed consent and comply&#xD;
             with the requirements of the study.&#xD;
&#xD;
          -  Pregnant or likely to be pregnant or nursing patient.&#xD;
&#xD;
          -  Known hypersensitivity to girentuximab or desferoxamine.&#xD;
&#xD;
          -  Renal insufficiency with Glomerular Filtration Rate : GFR ≤ 45 mL/min/ 1.73 m².&#xD;
&#xD;
          -  Persons deprived of their liberty, under a measure of safeguard of justice, under&#xD;
             guardianship or placed under the authority of a guardian.&#xD;
&#xD;
          -  Disorder precluding understanding of trial information or informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline ROUSSEAU, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut de Cancerologie de l'Ousest - ICO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline ROUSSEAU, MD</last_name>
    <phone>+ 33 240679931</phone>
    <email>caroline.rousseau@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia ALLAM, PhD</last_name>
    <phone>+33 240679826</phone>
    <email>nadia.allam@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROUSSEAU Caroline, MD</last_name>
      <phone>+33 2 40 67 99 00</phone>
      <email>caroline.rousseau@ico.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>89Zr-TLX250 (89Zirconium-TLX250)</keyword>
  <keyword>Positron Emission Tomography/Computerized Tomography (PET/CT) scan</keyword>
  <keyword>carbonic anhydrase IX (CAIX)</keyword>
  <keyword>89Zr- girentuximab (89Zirconium-girentuximab)</keyword>
  <keyword>89Zr-TLX250 PET/CT</keyword>
  <keyword>Metastatic Triple Negative Breast Cancer (TNBC)</keyword>
  <keyword>Human Anti-Chimeric Antibodies (HACA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

